Skip to main content

Table 1 Clinical characteristics of the study population (n = 173)

From: Thyroid transcription factor-1 as a prognostic indicator for stage IV lung adenocarcinoma with and without EGFR-sensitizing mutations

 

TTF-1 positive (n = 139)

TTF-1 negative (n = 34)

Total (n = 173)

P value

Age (mean ± SD), years

65.8 ± 11.4

66.4 ± 12.8

65.9 ± 11.7

0.787

  <  70

75 (81.5)

17 (18.5)

92 (53.2)

0.679

  = or > 70

64 (79.0)

17 (21.0)

81 (46.8)

 

Female, no. (%)

62 (91.2)

6 (8.8)

68 (39.3)

0.004

Smoking status, no. (%)

   

0.001

 Never smoker

69 (92.0)

6 (8.0)

75 (43.4)

 

 Current or former smoker

70 (71.4)

28 (28.6)

98 (56.6)

 

Stage, no. (%)

   

0.745

 M1a

41 (78.8)

11 (21.2)

52 (30.1)

 

 M1b

98 (81.0)

23 (19.0)

121 (69.9)

 

ECOG status, no. (%)

   

0.009

 0

67 (89.3)

8 (10.7)

75 (43.4)

 

 1–2

72 (73.5)

26 (26.5)

98 (56.6)

 

EGFR sensitizing mutation, no. (%)

   

< 0.001

 Wild-type

60 (67.4)

29 (32.6)

89 (51.4)

 

 Mutation

79 (94.0)

5 (6.0)

84 (48.6)

 
  1. Abbreviations: SD standard deviation, TTF-1 thyroid transcription factor 1, ECOG Eastern Cooperative Oncology Group, EGFR epidermal growth factor receptor